AAVantgarde is delighted to announce that we have closed a series B round worth $141m.   This milestone marks a significant step forward in our mission to transform eye care through our powerful gene delivery technologies.   We would like to extend our deepest gratitude to all our investors – both old and new – who made this round possible. Your support allows us to continue our work to transform the lives of patients with inherited retinal diseases for the better.   With the $141 million, we will:   Continue to develop AAVB-039, our candidate for Stargardt Disease caused by a mutation in the ABCA4 gene, completing both our observational STELLA study, and our ongoing interventional CELESTE Phase 1/2 (CELESTE) study.    Continue to develop AAVB-081, our lead candidate which aims to address retinitis pigmentosa (RP) secondary to Usher 1B due to a mutation in the MYO7A gene as it advances through its phase ½ study, LUCE-1.   For more information, please check our press release: https://lnkd.in/eFaQdpKN   The future of ophthalmology is bright – and we’re just getting started. Keep a look out for more great news from AAVantgarde. #SeriesB #AAVantgarde #Ophthalmology #Innovation #LifeSciences #IRDs